News summary

Innovative pharmaceutical company Ellis has achieved soaring performance with its best-selling drugs and strict fee control. Its share price has soared, and its market value has exceeded 30 billion yuan, becoming a star enterprise on the Science and Technology Innovation Board.

Newsletter text

The pharmaceutical sector, especially in the field of innovative drugs, is undergoing significant changes. With the increase in sales of some new drugs, this sector that once attracted much market attention is gradually emerging from the downturn.

Innovative drug companies face huge financial pressure during the research and development process and often rely on external financing. However, the capital environment has tightened during the U.S. dollar interest rate hike cycle, and many companies have to take measures to cut expenses to maintain operations, which has led to a certain extentscratchmakeymakeyThere were sharp fluctuations in stock prices.

Even with numerous challenges, investment opportunities in the field of innovative drugs still exist. A successfully marketed new drug can often drive the rapid rise of related companies and become the focus of the market. Ellis, an innovative pharmaceutical company listed on the Science and Technology Innovation Board, is a typical case.

Ellis 'recent earnings report showed strong growth in its performance. In 2023, the company's revenue will reach 20scratchmakeymakey.18 billion yuan, a year-on-year increase of 155.14%; net profit attributable to the parent company was 644 million yuan, a year-on-year increase of 393.54%. In the first quarter of 2024, revenue further increased to 743 million yuan, a year-on-year increase of 168.65%; net profit attributable to the parent company reached 306 million yuan, a year-on-year increase of 777.51%.

Ellis 'success is partly attributed to the inclusion of its innovative drug products in the national medical insurance catalog, which has significantly increased sales. In addition, the company has also achieved effective control of expenses, thereby ensuring a substantial increase in operating income.

Du Jinhao and Guo Jianhui, the founders of Ellis, laid a solid foundation for the company's development. Du Jinhao's business sense and Guo Jianhui's technical expertise complement each other and jointly promote the company's growth. Although Guo Jianhui's early death brought a test to the company, Du Jinhao relied on his firm belief to lead the company to overcome difficulties and successfully achieve transformation.

In the fierce market competition, Ellis successfully broke through through innovation in sales strategies and continuous increase in R & D investment. The third-generation EGFR inhibitor it developed has performed particularly well in the market and has become the main driving force for the company's performance growth.

Ellis 'future is full of hope. With the further expansion of the indications for formetinib, the company's market position is expected to be further consolidated. At the same time, the company's proactive sales strategy and R & D cost control will bring a stable profit period to the company. Ellis 'series of successful measures not only won market recognition, but also brought generous returns to investors.